Cartesian Therapeutics, Inc.
RNAC
$8.84
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -91.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -91.76% | |||
| Cost of Revenue | 4.97% | 32.50% | |||
| Gross Profit | -5.40% | -41.06% | |||
| SG&A Expenses | 22.63% | -13.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.70% | 16.13% | |||
| Operating Income | -10.02% | -20.78% | |||
| Income Before Tax | 140.25% | 61.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 140.25% | 57.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 140.25% | 57.68% | |||
| EBIT | -10.02% | -20.78% | |||
| EBITDA | -9.63% | -21.34% | |||
| EPS Basic | 133.62% | 61.10% | |||
| Normalized Basic EPS | -19.88% | -23.25% | |||
| EPS Diluted | 133.22% | 61.14% | |||
| Normalized Diluted EPS | -18.29% | -23.25% | |||
| Average Basic Shares Outstanding | 9.88% | 3.12% | |||
| Average Diluted Shares Outstanding | 11.35% | 3.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||